Longevity biotechnology is attracting investor attention as companies look for ways to extend healthy lifespan and treat diseases linked to ageing. The sector, also known as ageTech or longevity biotech, has seen rising investment in recent years as research moves beyond general wellness and towards technologies that may be developed into regulated medical products.
The main areas of research include epigenetic reprogramming, senolytics, artificial intelligence-led drug discovery and nutraceuticals such as NAD+ boosters. Each approach targets ageing from a different angle, but investors are increasingly focused on projects with measurable results, clinical relevance and a clear route to market.
Genflow Biosciences is a British biotechnology company developing gene therapies for age-related diseases. Its strategy is to target the biological mechanisms of ageing using adapted versions of genes linked with longer and healthier lives.
The company’s work centres on SIRT6, a gene associated with DNA maintenance and metabolic regulation. SIRT6 is also linked with centenarians, which makes it relevant to longevity research. Genflow is exploring whether this gene can be used in therapies designed to slow biological ageing and improve health in later life. The potential delivery method is intravenous infusion, although the products are not commercially available. They remain in clinical development.
Genflow’s pipeline could have relevance in age-related liver disease, muscle loss and eye health. These are sizeable areas of medical need as populations age, and they give the company several potential routes for development. Its gene therapy focus also helps separate it from companies selling supplements or pursuing less clinically defined anti-ageing concepts.
The company is also developing veterinary versions of its products to study their impact on biological ageing in pets. This may provide another way to test and understand the technology, while also opening a possible additional market over time.
Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives
